Tesaro Inc (TSRO)

153.19
2.54 1.63
NASDAQ : Health Care
Prev Close 155.73
Open 157.29
Day Low/High 152.80 / 159.25
52 Wk Low/High 29.51 / 94.01
Volume 674.54K
Avg Volume 990.10K
Exchange NASDAQ
Shares Outstanding 53.86M
Market Cap 8.36B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Market Recon: Worryingly, the Indices Seem to Be Almost Resting at Lofty Levels

Market Recon: Worryingly, the Indices Seem to Be Almost Resting at Lofty Levels

A mishap in northern Asia would be an awful catalyst even to ponder. But a less apocalyptic one would be oil.

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.

TESARO Announces Submission Of Investigational New Drug Application For Anti-LAG Antibody TSR-033 To The U.S. FDA

Phase 1 trial of TSR-033 planned to begin in mid-2017

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.

These Stocks Show a Change of Direction

These Stocks Show a Change of Direction

Finding bullish and bearish reversals in the market.

Biotech Premarket Movers: Cempra, Tesaro, Editas

Biotech Premarket Movers: Cempra, Tesaro, Editas

Cempra, Tesaro and Editas Medicine were among the biotech stock movers in premarket trading on Tuesday.

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

TESARO Announces U.S. FDA Approval Of ZEJULA™ (Niraparib) For Women With Recurrent Ovarian Cancer

- ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.

Incyte Pops on Continued Gilead Takeout Speculation

Incyte Pops on Continued Gilead Takeout Speculation

Shares were up 8% during intraday trading.

Invest Like a Venture Capitalist With These 4 Stocks

Invest Like a Venture Capitalist With These 4 Stocks

Here's a closer look at four of venture capital funds' favorite publicly traded names in 2017.

Forget the Snapchat IPO--Invest Like a Venture Capitalist With These 4 Stocks

Forget the Snapchat IPO--Invest Like a Venture Capitalist With These 4 Stocks

Venture capital funds added shares of these four publicly traded stocks to their portfolios last quarter. Should you?

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.